References in periodicals archive ?
Oragenics' research in the field of probiotic oral care has led to a pipeline of products ranging from novel anti-infectives to this IVIAT platform technology.
Oragenics, Inc. Receives U.S. Patent for IVIAT Platform Technology
from Laval University in Canada and is a co-inventor of ONI BioPharma's IVIAT platform technology that enables the rapid identification of novel and potentially important gene targets associated with the natural onset and progression of human infections.
Dr. Martin Handfield Joins ONI BioPharma as Director, Research and Development
IVIAT can quickly and easily identify in vivo induced genes in human infections without the use of animal models, facilitating the discovery of new targets for the development of vaccines, antimicrobials and diagnostics.
Oragenics Licenses Novel Technology for Gene Target Identification with Broad Potential to Generate Products for Human Health and Other Applications
Acronyms browser ?
Full browser ?